Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy.

Shuai LIU; Peng CHEN; Yan-Wei LIU; Xue-Nan GU; Xiao-Guang QIU; Bo LI

Return

Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy.

Author: Shuai LIU ¹ ; Peng CHEN ² ; Yan-Wei LIU ¹ ; Xue-Nan GU ² ; Xiao-Guang QIU ¹ ; Bo LI ¹
Author Information

1. Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
2. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Publication Type:Journal Article
Keywords: Chemotherapy; Non-Small Cell Lung Cancer; Recursive Partitioning Analysis; Stereotactic Radiosurgery; Tyrosine Kinase Inhibitors; Whole-Brain Radiation Therapy
MeSH: Adult; Aged; Aged, 80 and over; Brain Neoplasms; pathology; surgery; Carcinoma, Non-Small-Cell Lung; pathology; surgery; Female; Humans; Lung Neoplasms; pathology; surgery; Male; Middle Aged; Radiosurgery; methods; Treatment Outcome
From: Chinese Medical Journal 2018;131(10):1206-1213
CountryChina
Language:English
Abstract:
BackgroundThe role of postradiation systemic therapy in non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) was controversial. Thus, we explored the role of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) and graded prognostic assessment (GPA) in identifying population who may benefit from postradiation systemic therapy.
MethodsThe clinical data of NSCLC patients with documented BM from August 2007 to April 2015 of two hospitals were studied retrospectively. Cox regression was used for multivariate analysis. Survival of patients with or without postradiation systemic therapy was compared in subgroups stratified according to RTOG-RPA or GPA.
ResultsOf 216 included patients, 67.1% received stereotactic radiosurgery (SRS), 24.1% received whole-brain radiation therapy (WBRT), and 8.8% received both. After radiotherapy, systemic therapy was administered in 58.3% of patients. Multivariate analysis found that postradiation systemic therapy (yes vs. no) (hazard ratio [HR] = 0.361, 95% confidence interval [CI] = 0.202-0.648, P = 0.001), radiation technique (SRS vs. WBRT) (HR = 0.462, 95% CI = 0.238-0.849, P = 0.022), extracranial metastasis (yes vs. no) (HR = 3.970, 95% CI = 1.757-8.970, P = 0.001), and Karnofsky performance status (<70 vs. ≥70) (HR = 5.338, 95% CI = 2.829-10.072, P < 0.001) were independent factors for survival. Further analysis found that subsequent tyrosine kinase inhibitor (TKI) therapy could significantly reduce the risk of mortality of patients in RTOG-RPA Class II (HR = 0.411, 95% CI = 0.183-0.923, P = 0.031) or with a GPA score of 1.5-2.5 (HR = 0.420, 95% CI = 0.182-0.968, P = 0.042). However, none of the subgroups stratified according to RTOG-RPA or GPA benefited from the additional conventional chemotherapy.
ConclusionRTOG-RPA and GPA may be useful to identify beneficial populations in NSCLC patients with BM if TKIs were chosen as postradiation systemic therapy.